Comparison of thallium scintigraphy and positron emission tomography

Angiology

Volumn 48, Issue 10, 1997, Pages 843-853

  Niemeyer, M G ^a,b   Kuijper, A F M ^a   Meeder, J G ^b   Cramer, M J M ^c   Cleophas, A J M ^a   Van Der Wall, E E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c EEMLAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; FLUORODEOXYGLUCOSE F 18; NITROGEN 13; THALLIUM 201;

ARTICLE; CARDIOMYOPATHY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; HEART DILATATION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; POSITRON EMISSION TOMOGRAPHY; SCINTIANGIOGRAPHY;

EID: 0030750515     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979704801001     Document Type: Article

References (63)

1. Phelps ME, Mazziotta JC, Shelbert H: Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York: Raven Press, 1986.
2. Yamashita K, Tamaki N, Yonekura Y, et al: Regional wall thickening of left ventricle evaluated by gated positron emission tomography in relation to myocardial perfusion and glucose metabolism. J Nucl Med 32:679-685, 1991.
3. Grover-McKay M, Schwaiger M, Krivokapich J, et al: Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 13:317-324, 1989.
4. Niemeyer MG, Kuyper AFM, Gerhards LJ, et al: Nitrogen-13 ammonia perfusion imaging: Relation to metabolic imaging. Am Heart J 125:848-854, 1993.
5. Blanksma PK, Willemsen ATM, Meeder JG, et al: Quantitative myocardial mapping of perfusion and metabolism using parametric polar map displays in cardiac PET. J Nucl Med 36:153-158, 1995.
6. Meeder JG, Blanksma PK, Crijns HJGM, et al: Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability. Eur Heart J 16:1571-1577, 1995.
7. Walsh MN, Geltman EM, Brown MA, et al: Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-1 acetate in patients with myocardial infarction. J Nucl Med 30:1798-1808, 1989.
8. Armbrecht JJ, Buxton DB, Schelbert HR: Validation of 1[11c]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation 81:1594-1605, 1990.
9. Bonow RO, Dilsizian V: Assessing viable myocardium with thallium-201. Am J Cardiol 70:10E-17E, 1992.
10. Nielsen AP, Morris KG, Murdock R, et al: Linear relationship between the distribution of thallium-201 and blood flow in ischemic and nonischemic myocardium during exercise. Circulation 61:797-801, 1980.
11. Melin JA, Becker LC: Quantitative relationship between global left ventricular thallium uptake and blood flow: Effects of propranolol, ouabain, dipyridamole, and coronary occlusion. J Nucl Med 27:641-652, 1986.
12. Kuyper AFM, van Eck-Smit BLF, Niemeyer MG, et al: The role of scintigraphic techniques in the evaluation of functional results of coronary bypass grafting and percutaneous transluminal coronary angioplasry. Int J Card Imaging 9:49-58, 1993.
13. Beller GA, Gibson RS: Sensitivity, specificity and prognostic significance of noninvasive testing for occult or known coronary disease. Prog Cardiovasc Dis 29:241-270, 1987.
14. Wackers FJ, Fetterman R, Mattera JA, et al: Quantitative planar thallium-201 stress scintigraphy: A critical evaluation of the method. Semin Nucl Med 15:46-66, 1985.
15. Zijlstra F, Fioretti P, Reiber JH, et al: Which cineangiographically assessed anatomic variable correlates best with functional measurements of stenosis severity? A comparison of quantitative analysis of the coronary cineangiogram with measured coronary flow reserve and exercise/redistribution thallium-201 scintigraphy. J Am Coll Cardiol 12:686-691, 1988.
16. Pohost GM, Zir LM, Moore RH, et al: Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201 Circulation 55:294-302, 1977.
17. Dilsizian V, Bonow RO: Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation 87:1-20, 1993.
18. Cloninger KG, DePuey KG, Garcia EV, et al: Incomplete redistribution in delayed thallium-201 single photon emission computed tomographic (SPECT) images: An overestimation of myocardial scarring. J Am Coll Cardiol 12:955-963, 1988.
19. Kiat H, Berman DS, Maddahi J, et al: Late reversibility of tomographic myocardial thallium-201 defects: An accurate marker of myocardial viability. J Am Coll Cardiol 12:1456-1463, 1988.
20. Dilsizian V, Rocco TP, Freedman NMT, et al: Enhanced detection of ischemic but viable myocardium by reinjection of thallium after stress-redistribution imaging. N Engl J Med 323:141-146, 1990.
21. Dilsizian V, Bonow RO: Differential uptake and apparent thallium-201 "washout" after thallium reinjection options regarding early redistribution imaging or late redistribution imaging after reinjection. Circulation 85:1032-1038, 1992.
22. Schroeder H, Friedrich M, Topp H: Myocardial viability; what do we need? Eur J Nucl Med 20:792-803, 1993.
23. Dilsizian V, Smeltzer WR, Freedman NMT, et al: Thallium reinjection after stress-redistribution imaging. Does 24-hour delayed imaging after reinjection enhance detection of viable myocardium? Circulation 83:1247-1255, 1991.
24. van Eck-Smit BLF, van der Wall EE, Kuyper AFM, et al: Immediate thallium-201 reinjection following stress imaging: A time saving approach for detection of myocardial viability. J Nucl Med 34:737-743, 1993.
25. 13N ammonia and positron emission tomography in intact dogs. J Am Coll Cardiol 5:92-100, 1985.
26. 13N ammonia myocardial imaging at rest and exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation 80:1328-1337, 1989.
27. 13N ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 15:1032-1042, 1990.
28. 13N ammonia as an indicator of myocardial blood flow. Circulation 63:1259-1272, 1981.
29. 13N ammonia uptake in myocardial single cells indicating potential limitations in its applicability as a marker of myocardial blood flow. Circulation 71:387-393, 1985.
30. Kambara H, Fudo T, Hashimoto T, et al: Silent myocardial ischemia in patients with myocardial infarction: Evaluation with positron emission computed tomography. Jpn Circ J 53:1437-1443, 1989.
31. Gould KL: Clinical cardiac positron emission tomography: State of the art. Circulation 84[suppl I]:I-22-I-36, 1991.
32. 13N ammonia and positron computed tomography. Am J Cardiol 49:1197-1207, 1982.
33. 13N ammonia and high resolution positron emission computed tomography. Am Heart J 113:645-654, 1987.
34. Zimmermann R, Tillmans H, Knapp WH, et al: Regional myocardial nitrogen-13 glutamate uptake in patients with coronary artery disease: Inverse post-stress relation to thallium 201 uptake in ischemia. J Am Coll Cardiol 11:549-556, 1988.
35. Gould KL: Percent coronary stenosis: Battered gold standard pernicious relic, or clinical practicality? J Am Coll Cardiol 11:886-888, 1988.
36. Schwaiger M, Brunken RC, Krivokapich J, et al: Beneficial effect of residual anterograde flow on tissue viability as assessed by positron emission tomography in patients with myocardial infarction. Eur Heart J 8:981-988, 1987.
37. Brunken K, Schwaiger M, Grover-McKay M, et al: Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects. J Am Coll Cardiol 10:557-567, 1987.
38. 13N ammonia. Circulation 67:766-778, 1983.
39. Williams BR: Positron emission tomography for the assessment of ischemia and myocardial viability. J Myocardial Ischemia 2:33-64, 1990.
40. 18F-fluorodeoxyglucose. Circulation 83:26-37, 1991.
41. Sobel BE, Geltman EM, Tiefenbrunn AJ, et al: Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. Circulation 69:983-990, 1984.
42. Goldstein RA, Kirkeeide R, Smalling RW, et al: Changes in myocardial perfusion reserve after PTCA: Noninvasive assessment with positron tomography. J Nucl Med 28:1262-1267, 1987.
43. Tillisch J, Brunken R, Marschall R, et al: Reversibility of cardial wall-motion abnormalities predicted by positron tomography. N Engl J Med 314:884-888, 1986.
44. Demer LL, Gould KL, Goldstein R, et al: Noninvasive assessment of coronary collaterals in man by PET perfusion imaging. J Nucl Med 31:259-270, 1990.
45. 201Tl SPECT. Radiology 172:65-73, 1989.
46. Schelbert HR: Positron emission tomography for the assessment of myocardial viability. Circulation 84(suppl I):I-122-I-131, 1991.
47. Vaghaiwalla-Mody FV, Brunken RC, Warner Stevenson L, et al: Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilizing positron tomography. J Am Coll Cardiol 17:373-383, 1991.
48. Geldman EM, Smith JL, Beecher D, et al: Altered regional myocardial metabolism in congestive cardiomyopathy detected by positron tomography. Am J Med 74:773-785, 1983.
49. Perloff JK, Roberts WC, Deleon ACJ, et al: The distinctive electrocardiogram of Duchenne's progressive muscular dystrophy. An electrocardiographic pathologic correlative study. Am J Med 42:179-188, 1967.
50. Perloff JK, Henze E, Schelbert HR: Alterations in regional myocardial metabolism perfusion, and wall motion in Duchenne's muscular dystrophy studied by radionuclide imaging. Circulation 69:33-42, 1984.
51. Endo M, Yoshida K, Iinuma TA, et al: Noninvasive quantification of regional myocardial blood flow and ammonia extraction fraction using nitrogen-13 ammonia and positron emission tomography. Ann Nucl Med 1:1-6, 1987.
52. 13N ammonia and PET. Am J Physiol Imaging 4:97-104, 1989.
53. Camici P, Chiriatti G, Lorenzoni R, et al: Coronary vasodilatation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with nitrogen-13 ammonia and positron emission tomography. Am Coll Cardiol 17:879-886, 1991.
54. Kehtarnavaz N, Defigueiredo RJP: A novel surface reconstruction and display method for cardiac PET imaging. IEEE Trans Medical Imaging MI-3:108-115, 1984.
55. Posma JL, Blanksma PK, van de Wall EE, et al: Redistribution of myocardial perfusion during permanent dual chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy: A quantitative positron emission tomography study. Heart 75:511-513, 1996.
56. Tamaki N, Ohtani H, Yamashita K, et al: Metabolic activity in the areas of new fill-in after thallium 201 reinjection: Comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 32:673-678, 1991.
57. Tamaki N, Kawamoto M, Takahashi N, et al: Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: Comparison with stress thallium imaging. J Am Coll Cardiol 22:1621-1627, 1993.
58. Altehoefer C, Dahl J vom, Buell U, et al: Comparison of thallium 201 single-photon emission tomography after rest injection and fluorodeoxyglucose positron emission tomography for assessment of myocardial viability in patients with chronic coronary artery disease. Eur J Nucl Med 21:37-45, 1994.
59. Dreyfus GD, Duboc D, Blasco A, et al: Myocardial viability assessment in ischemic cardiomyopathy: Benefits of coronary revascularization. Ann Thorac Surg 57:1402-1408, 1994.
60. Go RT, Marwick TH, MacIntyre WJ, et al: A prospective comparison of rubidium-82 PET and thallium 201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med 31:1899-1905, 1990.
61. Stewart RE, Schwaiger M, Molina E, et al: Comparison of rubidium-82 positron emission tomography and thallium 201 SPECT imaging for detection of coronary artery disease. Am J Cardiol 67:1303-1310, 1991.
62. Wackers FJTh: Planar, SPECT, PET: The quest to predict the unpredictable? J Nucl Med 31:1906-1909, 1990.
63. 18F-fluorodexyglucose and thallium 201 in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 86:1125-1137, 1992.